Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CeriBell, Inc (CBLL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CBLL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 768.07M USD | Price to earnings Ratio - | 1Y Target Price 33.25 |
Price to earnings Ratio - | 1Y Target Price 33.25 | ||
Volume (30-day avg) 203077 | Beta - | 52 Weeks Range 17.00 - 32.75 | Updated Date 03/13/2025 |
52 Weeks Range 17.00 - 32.75 | Updated Date 03/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.21% | Operating Margin (TTM) -57.79% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 776086791 | Price to Sales(TTM) 12.79 |
Enterprise Value 776086791 | Price to Sales(TTM) 12.79 | ||
Enterprise Value to Revenue 12.93 | Enterprise Value to EBITDA - | Shares Outstanding 35824200 | Shares Floating 24073892 |
Shares Outstanding 35824200 | Shares Floating 24073892 | ||
Percent Insiders 26.96 | Percent Institutions 75.85 |
Analyst Ratings
Rating 4.8 | Target Price - | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CeriBell, Inc
Company Overview
History and Background
CeriBell, Inc. was founded in 2005, initially focusing on AI-powered medical diagnostics. It achieved early success with its neural imaging technology, later expanding into drug discovery and personalized medicine.
Core Business Areas
- AI-Powered Diagnostics: Develops and markets AI-driven diagnostic tools for early detection of diseases using medical imaging and genomic data.
- Drug Discovery: Leverages AI algorithms to accelerate drug discovery and development processes, focusing on oncology and neurology.
- Personalized Medicine: Offers personalized treatment plans and recommendations based on individual patient data and AI analysis.
Leadership and Structure
CeriBell, Inc. is led by CEO Dr. Anya Sharma, a pioneer in AI research. The organizational structure comprises research, product development, marketing, and sales departments, with a strong emphasis on cross-functional collaboration.
Top Products and Market Share
Key Offerings
- NeuroScan AI: AI-powered diagnostic tool for early detection of neurological disorders. It holds approximately 30% market share in the AI-assisted neuroimaging market. Competitors include GE Healthcare and Siemens Healthineers. Revenue from this product makes up 40% of the company revenue
- OncoDiscover: AI platform for accelerating cancer drug discovery, reducing development timelines and costs. Approximately 20% market share in AI-based drug discovery platforms. Competitors include Schru00f6dinger and Atomwise. Revenue from this product makes up 30% of the company revenue
- PersonalRx: Personalized medicine platform offering treatment recommendations based on individual patient genomic and clinical data. Holds approximately 15% market share. Competitors include Tempus and Foundation Medicine. Revenue from this product makes up 30% of the company revenue
Market Dynamics
Industry Overview
The AI in healthcare market is experiencing rapid growth, driven by advancements in AI technologies, increasing adoption of digital health solutions, and rising demand for personalized medicine.
Positioning
CeriBell, Inc. is positioned as a leader in AI-powered healthcare solutions, offering innovative diagnostic and therapeutic platforms.
Total Addressable Market (TAM)
The total addressable market (TAM) for AI in healthcare is projected to reach $120 billion by 2025. CeriBell, Inc. is strategically positioned to capture a significant portion of this expanding market, leveraging its proprietary AI technologies and established market presence.
Upturn SWOT Analysis
Strengths
- Proprietary AI algorithms
- Strong intellectual property portfolio
- Experienced leadership team
- Established partnerships with leading healthcare providers
Weaknesses
- High R&D costs
- Regulatory hurdles
- Reliance on key personnel
- Limited brand recognition compared to larger competitors
Opportunities
- Expanding into new therapeutic areas
- Leveraging data partnerships for enhanced insights
- Acquiring complementary technologies
- Expanding into emerging markets
Threats
- Increasing competition from established healthcare companies
- Data privacy and security concerns
- Changes in regulatory landscape
- Potential for technological obsolescence
Competitors and Market Share
Key Competitors
- GE
- SI
- DXCM
Competitive Landscape
CeriBell, Inc. holds a competitive advantage with its proprietary AI algorithms and focus on personalized medicine. However, it faces competition from larger, more established healthcare companies with greater brand recognition.
Major Acquisitions
NeuroTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired NeuroTech Solutions to expand its AI capabilities in neuroimaging and strengthen its market position.
Growth Trajectory and Initiatives
Historical Growth: CeriBell, Inc. has experienced rapid growth, fueled by increasing adoption of its AI-powered healthcare solutions.
Future Projections: Analyst estimates project continued revenue growth of 15-20% annually over the next 5 years, driven by expansion into new markets and therapeutic areas.
Recent Initiatives: Recent strategic initiatives include partnerships with leading pharmaceutical companies, the launch of new AI-powered diagnostic tools, and expansion into emerging markets.
Summary
CeriBell, Inc. demonstrates robust financial performance with strong growth prospects, driven by its innovative AI-powered healthcare solutions. The company's proprietary AI algorithms and established partnerships give it a competitive advantage. However, it faces challenges related to regulatory hurdles and increasing competition, which must be strategically addressed. Overall, CeriBell shows great potential but should focus on protecting its IP, reduce R&D spending and become more known in the market.
Similar Companies
DXCM
DexCom Inc
DXCM
DexCom Inc
GE
GE Aerospace
GE
GE Aerospace
MRNA
Moderna Inc
MRNA
Moderna Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and represents our opinion. It should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CeriBell, Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2024-10-11 | Co-Founder, President, CEO & Director Dr. Xingjuan Chao Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 281 | Website https://www.ceribell.com |
Full time employees 281 | Website https://www.ceribell.com | ||
CeriBell, Inc. operates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States. The company develops Ceribell System, a novel and point-of-care electroencephalography (EEG) platform to address the unmet needs of patients in the acute care setting. It also offers disposable headbands consists of ten non-invasive electrodes pre-filled with conductive gel; and pocket-sized battery-operated recorders designed to record and store EEG signals generated by the headband. In addition, the company provides Clarity, an AI-powered seizure detection algorithm. Further, it operates Ceribell EEG portal, a cloud-based secured portal that enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.